Iris Energy에 대한 매도 수량은 투자자에게 Iris Energy의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Iris Energy (NASDAQ:IREN) 주식, 공매도 수량 보고

Iris Energy

Iris Energy Ltd is a Bitcoin mining company. It builds, owns, and operates data centers and electrical infrastructure for the mining of Bitcoin powered by renewable energy. The company's mining operations generate revenue by earning Bitcoin through a combination of block rewards and transaction fees from the operation of its specialized computers called Application-specific Integrated Circuits and exchanging these Bitcoin for currencies such as USD or CAD on a daily basis.

Equities

News

Markets

$BTC

AFRM

CRWD

IREN

NVDA

TSLA

수요일 미국 주요 지수는 다우존스 산업평균지수가 0.4% 하락한 41,091.42, S&amp;P 500 지수가 0.6% 하락한 5,592.18로 하락 마감했다. 나스닥지수는 1.1% 하락한 17,556.03에 마감되었다.
이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:
엔비디아(NASDAQ:NVDA)

화요일 주목받은 5주식: 엔비디아, 어펌, 크라우드스트라이크, 아이리스 에너지, 테슬라

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

After-Hours Center

Movers

아이리스 에너지(NASDAQ:IREN)는 수요일 시장 마감 후에 회계연도 재무 결과를 발표했다. 이 발표로 주가는 시간외 거래에서 5% 이상 상승했다. 다음은 보고서의 주요 수치들이다.

아이리스 에너지의 주식이 2024 회계연도 실적 발표 후 시간외 거래에서 5% 이상 상승

Iris Energy Ltd

Iren SpA

KAVL

Delta Corp Holdings Advances Business Combination With Kaival Brands Through Confidential Submission Of Draft Registration Statement With SEC, Creating New Publicly Listed Holding Company

Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) has introduced a new initiative aimed at increasing electric vehicle sales by addressing customer concerns.
What Happened: The &#8220;Ford Power Promise&#8221; program, starting Tuesday, offers benefits like free home-charging installation for buyers or lessees of new Ford EVs, including the F-150 Lightning and Mustang Mach-E. The initiative aims to alleviate financial burdens and educate new EV owners, CNBC <a href="https://www.cnbc.com/2024/09/30/ford-ev-benefits-program-aims-to-boost-sales.html">reported</a> on Monday.
Marin Gjaja, COO of Ford&#8217;s Model e EV business, stated, &#8220;Filling up at home is really key, but so is confidence in the durability and life of the battery.&#8221; 
The program addresses &#8220;change anxiety,&#8221; a term Ford uses to describe the fear of transitioning from gas to electric vehicles.
Benefits include installation of a $1,310 level-two home charger, 24-hour advisor service, and roadside assistance for five years or 60,000 miles. Customers can opt for a $2,000 cash equivalent if they don&#8217;t need a home charger. The program&#8217;s free charger installation is initially available for the fourth quarter, with potential extensions.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41071876/mojo-is-back-at-tesla-says-tech-analyst-dan-ives-ahead-of-q3-deliveries?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla &#8216;Mojo Is Back,&#8217; Tech Analyst Dan Ives Says Ahead Of Q3 Deliveries</a>
Ford also plans to highlight its 8-year or 100,000-mile battery warranty, which many consumers are unaware of. The company did not disclose the potential cost of the new program.
Why It Matters: Ford&#8217;s latest initiative comes on the heels of a significant <a href="https://www.benzinga.com/news/24/09/40745466/fords-august-ev-sales-surge-29-driven-by-cybertruck-rival-f-150-lightning-despite-its-slowing-future">surge in its EV sales</a>. In August, Ford reported a 29% increase in electric vehicle sales, driven largely by the F-150 Lightning, which saw a 161% jump in sales.
Additionally, Ford has been enhancing its EV offerings with new features to <a href="https://www.benzinga.com/news/24/09/40920761/ford-evs-creating-joy-with-built-in-karaoke-add-popular-tesla-feature-to-select-models">attract more customers</a>. Recently, the company announced that select Ford EVs, including the F-150 Lightning, will soon feature built-in karaoke, a popular feature in Tesla vehicles.
The program comes at a time when EV sales are <a href="https://www.benzinga.com/news/24/09/41060572/ev-sales-expected-to-gain-momentum-in-us-in-q3-even-as-market-leader-tesla-is-projected-to-decline-r">predicted to gain momentum</a> in the third quarter of 2024 and see an 8% growth year-on-year, as per Cox Automotive analysis.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/24/09/40972034/elon-musk-responds-as-california-congressman-slams-bureaucratic-roadblocks-for-spacex-program-agenci?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Responds As California Congressman Slams Bureaucratic Roadblocks For SpaceX Program: &#8216;Agencies Need To Prioritize Enabling Launches And Not Standing In Their Way&#8217;</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Tech

General

Ford Launches New Benefits Program To Address 'Change Anxiety' Amid Slowdown In EV Sales

The most oversold stocks in the utilities sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 3</a>0, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>)</h3>
<ul>
<li>On Sept. 17, VivoPower announced a heads of agreement to merge with Future Automotive Solutions and Technologies. The company's stock fell around 42% over the past month and has a <a href="https://www.benzinga.com/quote/VVPR">52-week low of $1.02</a>.</li>
<li>RSI Value: 28.40</li>
<li>VVPR Price Action: Shares of VivoPower International fell 7% to close at $1.06 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1"> latest VVPR news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30040649/image-229.png" alt="" class="wp-image-571825" style="width:669px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30040649/image-229.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30040649/image-229-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30040649/image-229-768x711.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Alternus Clean Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Sept. 19, Alternus Clean Energy announced the termination of Membership Interest Purchase and Sales Agreement (MIPSA) for Portfolio of Solar Parks. Alternus CEO Vincent Browne commented, &#8220;It is unfortunate that we cannot continue with this transaction as planned. However, this is just one of many identified strategic acquisitions and business growth areas underway for Alternus, such as the recent joint venture announcement with Hover Energy and other projects in review and under negotiation. We remain fully committed to the renewable energy market in the United States, whether via the acquisition of operating or ready-to-build projects and look forward to sharing these as soon as we can.&#8221; The company's stock fell around 27% over the past month. It <a href="https://www.benzinga.com/quote/ALCE">has a 52-week low</a> of $0.15.</li>
<li>RSI Value: 25.93</li>
<li>ALCE Price Action: Shares of Alternus Clean Energy fell 2% to close at $0.16 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1">trend in ALCE stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="923" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30040514/image-228.png" alt="" class="wp-image-571818" style="width:646px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30040514/image-228.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30040514/image-228-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30040514/image-228-768x705.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41075978/top-4-materials-stocks-that-may-implode-in-q3">Top 4 Materials Stocks That May Implode In Q3</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Trading Ideas

ALCE

VVPR

Top 2 Utilities Stocks That Could Blast Off This Quarter

RDGL

Vivos Inc. Extendeds IsoPet Precision Radionuclide TherapyTM To Exotics

Goldman Sachs analyst Alexander Blostein maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Buy and raises the price target from $47 to $52.

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on Brookfield Asset Mgmt, Raises Price Target to $52

Offerings

CLNN

Clene Announces $7.3M Registered Direct Offering And Concurrent Private Placements, Issuing 742,626 Shares And Warrants Priced At Market Under Nasdaq Rules

Vishay Precision Group Acquires Nokra; Terms Not Disclosed

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the communication services sector.
<h3 class="wp-block-heading">Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</h3>
<ul>
<li>Dividend Yield: 6.04%</li>
<li>B of A Securities analyst David Barden maintained a Neutral rating and raised the price target from $41 to $45 on Sept. 26. This analyst has an accuracy rate of 65%.</li>
<li>Citigroup analyst Michael Rollins maintained a Buy rating and increased the price target from $47 to $49 on Sept. 25. This analyst has an accuracy rate of 77%</li>
<li>Recent News: Vay collaborated with Verizon Communications to integrate Verizon 5G connectivity into Vay's fleet of teleoperated electric vehicles.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1"> latest VZ news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="858" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30045916/image-230.png" alt="" class="wp-image-571915" style="width:697px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30045916/image-230.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30045916/image-230-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30045916/image-230-768x719.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</h3>
<ul>
<li>Dividend Yield: 5.07%</li>
<li>Tigress Financial analyst Ivan Feinseth maintained a Buy rating and raised the price target from $29 to $30 on Sept. 27. This analyst has an accuracy rate of 73%.</li>
<li>Citigroup analyst Michael Rollins maintained a Buy rating and increased the price target from $21 to $24 on Sept. 11. This analyst has an accuracy rate of 77%</li>
<li>Recent News: The company's board of directors declared a quarterly dividend of $27.75 cents per share on common shares.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1">latest T news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30045930/image-231.png" alt="" class="wp-image-571917" style="width:683px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30045930/image-231.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30045930/image-231-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30045930/image-231-768x713.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>)</h3>
<ul>
<li>Dividend Yield: 4.17%</li>
<li>Barclays analyst Julien Roch maintained an Equal-Weight rating and cut the price target from $35 to $34 on July 25. This analyst has an accuracy rate of 62%.</li>
<li>Morgan Stanley analyst Benjamin Swinburne downgraded the stock from Equal-Weight to Underweight and cut the price target from $34 to $28 on July 22. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On Sept. 18, Interpublic named Alex Hesz as Chief Strategy Officer.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1">trend in IPG stock.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent093024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30050005/image-232.png" alt="" class="wp-image-571918" style="width:661px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30050005/image-232.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30050005/image-232-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30050005/image-232-768x704.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41075978/top-4-materials-stocks-that-may-implode-in-q3">Top 4 Materials Stocks That May Implode In Q3</a></li>
</ul>

Dividends

Wall Street's Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Monday.
Shares of Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/STLA/news">updated its 2024 guidance.</a>
Stellantis said it now expects FY24 operating margin of 5.5%-7.0%, down from its prior double-digit growth expectations.
Stellantis shares dipped 11.6% to $14.20 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) shares dipped 13% to $7.34 in pre-market trading after gaining over 5% on Friday.</li>
<li>Corvus Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) declined 11.6% to $4.55 in today's pre-market trading.</li>
<li>Venus Concept Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined 10.4% to $0.62 in pre-market trading. Venus Concept shares jumped around 20% on Friday after the company announced a $15 million debt-to-equity exchange transaction.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares fell 8.3% to $7.51 in pre-market trading.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) shares fell 6.1% to $3.86 in pre-market trading. Northland Capital Markets, last week, initiated coverage on the stock with an Outperform rating and announced a $6 price target.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares declined 6.1% to $165.51 in pre-market trading amid a decline in Bitcoin prices.</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) shares fell 5.2% to $12.40 in pre-market trading amid a decline in Bitcoin prices.</li>
<li>Bit Digital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) shares slipped 5.2% to $3.45 in pre-market trading amid a decline in Bitcoin prices.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41075978/top-4-materials-stocks-that-may-implode-in-q3">Top 4 Materials Stocks That May Implode In Q3</a></li>
</ul>

APLD

BTBT

BTDR

CIFR

CRVS

MSTR

STLA

VERO

Stellantis, MicroStrategy, Bit Digital And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Goldman Sachs analyst Alexander Blostein maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Buy and raises the price target from $145 to $160.

ARES

Goldman Sachs Maintains Buy on Ares Management, Raises Price Target to $160

CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) is set to face renewed pressure as hedge fund Glenview Capital Management, led by founder Larry Robbins, plans to meet top executives, including CEO Karen Lynch, to discuss operational improvements.
The meeting with Glenview comes as part of Robbins&#8217; broader strategy to push for change, the Wall Street Journal reports.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/08/40437498/pharmacy-chains-like-cvs-health-walgreens-boots-alliance-confront-shifting-consumer-habits-and-pro" rel="noreferrer noopener">Pharmacy Chains Like CVS Health, Walgreens Boots Alliance Confront Shifting Consumer Habits And Profit Pressures</a>.
Robbins, who has built a substantial $700 million position in CVS, sees potential for the company to revitalize its struggling business without resorting to a breakup.
Robbins is expected to propose cost-cutting and restructuring strategies but will not push for a breakup of CVS. Another hedge fund has also built a notable position in the company, hinting at further pressure from investors.
CVS, one of the largest healthcare companies in the U.S., has seen its stock tumble 24% year-to-date amid multiple earnings downgrades.
In the second quarter, the pharmacy chain reported adjusted EPS of&nbsp;$1.83&nbsp;decreased from&nbsp;$2.21&nbsp;in the prior year, beating the consensus of $1.73. The fall is primarily due to a decline in the Health Care Benefits segment&#8217;s operating results, which reflect continued utilization pressure and the unfavorable impact of the company&#8217;s Medicare Advantage star ratings for the 2024 payment year within <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40220306/cvs-health-reports-mixed-q2-earnings-lowers-2024-outlook-reshuffles-segment-management" rel="noreferrer noopener">the Medicare product line</a>.
CVS Health revised its adjusted EPS guidance to $6.40-$6.65&nbsp;from at least&nbsp;$7.00 versus the consensus of $6.98, reflecting continued pressure in the Health Care Benefits segment.
The Wall Street report <a target="_blank" href="https://www.wsj.com/health/healthcare/glenview-capital-plans-push-for-changes-at-cvs-5df8aa8a?mod=latest_headlines" rel="noreferrer noopener">adds</a> that CVS had heavily invested in attracting seniors to its Aetna Medicare plans, but the move backfired, squeezing margins. The company is now revising its Medicare approach for 2025 to address these issues.
CVS Health decided to make leadership changes based on the current performance and outlook for the Health Care Benefits segment.&nbsp;
Brian Kane&nbsp;quit, and Karen Lynch,&nbsp;the CEO, assumed direct leadership of the Health Care Benefits segment.
Karen and Tom Cowhey, CVS Health&#8217;s CFO, oversee the business&#8217;s day-to-day management.
Recently, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health&#8217;s Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">price of insulin medications</a>.
The FTC has also highlighted significant concerns regarding consolidating pharmacies and health insurance companies, focusing on the influence of a few dominant PBMs <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">on prescription drug prices</a>.
Price Action: CVS stock is up 3.27% at $63.39 during the premarket session at last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41075259/udemy-downgrade-analyst-warns-of-negative-riskreward-profile-while-demand-is-weak" target="_blank" rel="noreferrer noopener">Udemy Downgrade: Analyst Warns Of Negative Risk/Reward Profile While Demand Is Weak</a>.</li>
</ul>
Photo: Around the World Photos via Shutterstock

Large Cap

Health Care

Media

CVS Health in Focus as Activist Investor Prepares for High-Level Talks

ASST

Asset Entities Announces At-The-Market Offering Of Up To $1.79M In Class B Common Stock

Cantor Fitzgerald analyst Louise Chen reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

Biotech

WINT

Windtree Announces Worsening Heart Failure Reported As A Serious Adverse Event Occurred Less Frequently In The Istaroxime Group Compared To Placebo 5.3% Versus 18.2%, Respectively.

NIO: 15% &#x7C; <a href="https://www.benzinga.com//node/41089541">Nio shares are trading higher after investors agreed to invest an aggregate of 3.3 billion yuan in its Nio China subsidiary while the company agreed to invest 10 billion yuan.</a>
&nbsp;
PRME: 33% &#x7C; <a href="https://www.benzinga.com//node/41088636">Prime Medicine Enters Strategic Research Collaboration And License Agreement With Bristol Myers Squibb; Prime Medicine To Receive $110M Upfront, With Potential For More Than $3.5B In Milestones</a>
&nbsp;
BL: 4% &#x7C; <a href="https://www.benzinga.com//node/41089664">BlackLine shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $60 to $70.</a>

PRME

Market-Moving News for September 30th

Billionaire investor and investment guru <a href="https://www.benzinga.com/topic/warren-buffett">Warren Buffett </a>once shared the thumb rule he uses when to give up on a stock and in the process explained why investors are better off than business tycoons such as Andrew Carnegie or John Rockefeller.
What Happened: &#8220;I love it when the things we buy go down,&#8221; <a href="https://www.youtube.com/watch?v=cSU3y0N60XU">said</a> Buffett in a 2014 Fortune Magazine interview. He said he would get &#8220;euphoric when the stocks are down because he can buy more of something he owned. On the other hand, with their stocks, people think the stock knows more than they do, he said.
&#8220;When the stock goes down, they say the stock is telling them something&#8230; and what it&#8217;s telling me is I can get more for my money,&#8221; the Berkshire Hathaway CEO said. But they take it as a kind of referendum on themselves and make it as a &#8220;me versus stock&#8221; and say if they get back what they paid, they are going to sell the stock irrespective of what they paid, he said.
&#8220;Stock doesn&#8217;t care what you paid; you have to remember the stock doesn&#8217;t even care that you own it; you are nothing to the stock; that stock is everything to you,&#8221; Buffett said.
The only question with every stock, every day is to look into &#8220;Can I get more for my money someplace else,&#8221; he said, adding that investors get a chance to be in thousands and thousands of great businesses and their prices change all the time and so do their relative valuation.
See Also: <a href="https://www.benzinga.com/money/best-value-stocks">Best Value Stocks</a>
Since an investor can make the exchange at a very low cost these days, either with low commissions or nothing, they can always shift from one business to another, Buffett said. Investors have an advantage over Carnegie, who was in the steel business or Rockefeller who was in the oil business, he said. The billionaire said these businessmen couldn&#8217;t immediately shift to something like retailing or rearrange their business empire as an investor can with the portfolio they owned. The portfolio can be rearranged at a moment&#8217;s notice with practically no cost, he said, adding that this is a huge advantage.
&#8220;There is nothing about the price action of the stock that tells you whether you should keep owning; what tells you whether you should keep owning it is what you expect the company to do in the future versus the price at which it&#8217;s selling now compared to the other opportunities of businesses you think you know equally well and make that same comparison and that&#8217;s all there is to owning stocks,&#8221; Buffett said.
Why It&#8217;s Important: Buffett swears by an investment philosophy called value investing, which advocates picking stocks that appear to be trading for less than their intrinsic or book value. He has been very successful with the strategy and the success of Berkshire is a testament to it. The company, which owns holding companies primarily in the insurance and transportation businesses, as well as portfolio stocks, is now the eighth most valued global corporation, standing head-on-head with tech stocks.
Amid the current economic uncertainty, Buffett has shown a preference for accumulating a huge cash pile. At the end of the second quarter, the company <a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr">had a massive cash pile of $277 billion. </a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41018183/did-aping-warren-buffett-and-hedge-fund-managers-bring-success-to-this-ai-powered-etf-that-launc">Did Aping Warren Buffett And Hedge Fund Managers Bring Success To This AI-Powered ETF That Launched Last Week?</a></li>
</ul>
Photo: mark reinstein/Shutterstock.com

Education

Warren Buffet Tells Investors To Give Up On 'Me Vs. Stock' Approach: 'What Tells You Whether You Should Keep Owning A Stock Is…'

Wedbush analyst David Nierengarten reiterates Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) with a Outperform and maintains $15 price target.

INZY

Wedbush Reiterates Outperform on Inozyme Pharma, Maintains $15 Price Target

BIOR

Biora Therapeutics' Award-Winning Abstract To Be Presented At American College Of Gastroenterology Annual Meeting

ISO Certification paves the way to OEM relationships which could include direct and indirect sales to global car makers such as Rivian, Tesla, Ford, General Motors, Hyundai, Honda, Stellantis, Nissan, and Toyota. &nbsp;
West Seneca, New York, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Worksport Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) ("Worksport" or the "Company"), a U.S.-based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors is thrilled to announce that it is progressing towards achievement of ISO 9000 certification at its state-of-the-art West Seneca, NY factory anticipated by early-mid 2025. This certification reflects Worksport's commitment to quality manufacturing and is expected to support potential growth in key future markets including government contracts, Original Equipment Manufacturers ("OEM") relationships and larger distribution networks. OEM relationships may lead to future direct and indirect sales opportunities to domestic car brands such as Rivian, Tesla, Ford, General Motors, Hyundai, Honda, Stellantis, Nissan, and Toyota.

WKSP

Worksport Provides Progress Update On ISO 9000 Certification,  Paving The Way To OEM Relationships Which Could Include Direct And Indirect Sales To Global Car Makers Such As Rivian, Tesla, Ford, General Motors, Hyundai, Honda, Stellantis, Nissan, And Toyota

Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
NYHA heart failure classification was improved up to 72 hours with a serious adverse event profile generally similar to placebo
WARRINGTON, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- &nbsp;Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced positive topline clinical results for its Phase 2b SEISMiC Extension Study of istaroxime in heart failure patients in early cardiogenic shock.
Early cardiogenic shock is caused by a failing heart and is characterized by low blood pressure, leaving the patient at risk of developing inadequate blood flow to vital organs leading to high morbidity and mortality. Istaroxime is a novel first-in-class investigational therapy that is intended to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining renal function with a generally favorable safety profile. Istaroxime has been studied in four positive Phase 2 trials enrolling patients with acute heart failure and early cardiogenic shock due to heart failure.

Windtree Announces Positive Phase 2b Topline Clinical Results With Istaroxime Significantly Improving Cardiac Function And Blood Pressure In Heart Failure Patients In Early Cardiogenic Shock; The Study Met Its Primary Endpoint In Significantly Improving Systolic Blood Pressure Over Six Hours, With The Combined Part A And Part B Seismic Istaroxime Group Performing Significantly Better Compared To The Placebo Group

CleanSpark Offers A Unique Proposition And Is Now Heading To Undervaluation (Rating Upgrade)

Iris Energy (IREN) has released an update. Iris Energy Limited, also known as IREN, has published its consolidated annual financial report and dire...

Iris Energy Leadership Touts Strong Industry Expertise

Iris Energy (IREN) has released an update. Iris Energy Limited has expanded its AI Cloud Services by purchasing 1,080 NVIDIA H200 GPUs, projecting ...

Iris Energy Boosts AI Services and Bitcoin Mining

Iris Energy to increase AI cloud services to 10% of earnings, shares up

Iris Energy to increase AI cloud services to 10% of earnings; IREN shares up

Riot Platforms Offers Asymmetric Upside Potential At Full Capacity

Iris Energy To Benefit From Its AI Cloud Services Expansion

Iris Energy (IREN) has released an update. Iris Energy Limited (IREN) has achieved a significant milestone by increasing its installed capacity to ...

Iris Energy Surpasses Milestone with Expansion Plans

Iris Energy achieves 20 EH/s, on track for 31 EH/s

Iris Energy (IREN – Research Report), the Financial sector company, was revisited by a Wall Street analyst today. Analyst Gautam Chhugani from Bern...

Iris Energy: A Strong Buy on Expansion and Efficiency

BITF

CLSK

CORZ

CORZR

CORZW

CORZZ

CRZWQ

MARA

RIOT

Press Releases

IRIS ENERGY LIMITED ANNOUNCEMENT: If You Have Suffered Losses in Iris Energy Limited (NASDAQ: IREN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

IREN to increase AI Cloud Services to 10% of earnings

Rosen Law Firm Encourages Iris Energy Limited Investors to Inquire About Securities Class Action Investigation - IREN

Legal

IREN achieves 20 EH/s milestone

Amplitude

AvePoint

Blend Labs

Bitdeer Technologies Group - Ordinary Shares

Bitdeer Technologies

Cipher Mining

Sprinklr

E2open Parent Holdings, Inc.Class A Common Stock

E2open Parent Holdings

EverCommerce

Five9

Jamf Holding

Karooooo

MeridianLink

Matterport

NextNav

Opera Limited - American Depositary Shares

Opera

PagerDuty

LiveRamp Holdings

SEMrush Holdings, Inc. Class A Common Stock

SEMrush Hldgs

SoundHound AI, Inc. - Class A Common Stock

SoundHound AI

Sprout Social, Inc - Class A Common Stock

Sprout Social

Tuya Inc. American Depositary Shares, each representing one Class A Ordinary Share

Comments

Iris Energy

매도 수량

Iris Energy (NASDAQ:IREN) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌